149 related articles for article (PubMed ID: 26133057)
1. Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart.
Kim YI; Kim JH; Lee TY; Lee KW
J Ocul Pharmacol Ther; 2015; 31(6):335-9. PubMed ID: 26133057
[TBL] [Abstract][Full Text] [Related]
2. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC
Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
[TBL] [Abstract][Full Text] [Related]
3. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
4. Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
Pajic B;
Curr Med Res Opin; 2003; 19(2):95-101. PubMed ID: 12740152
[TBL] [Abstract][Full Text] [Related]
5. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study.
Francis BA; Du LT; Berke S; Ehrenhaus M; Minckler DS;
J Clin Pharm Ther; 2004 Aug; 29(4):375-80. PubMed ID: 15271105
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma.
Eren MH; Gungel H; Altan C; Pasaoglu IB; Sabanci S
J Ocul Pharmacol Ther; 2012 Aug; 28(4):381-6. PubMed ID: 22320418
[TBL] [Abstract][Full Text] [Related]
7. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma.
Pajic B; Pajic-Eggspuehler B; Häfliger IO
Curr Med Res Opin; 2010 Sep; 26(9):2213-9. PubMed ID: 20673200
[TBL] [Abstract][Full Text] [Related]
9. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
[TBL] [Abstract][Full Text] [Related]
10. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices.
Gugleta K; Orgül S; Flammer J
Curr Med Res Opin; 2003; 19(4):330-5. PubMed ID: 12841926
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
Shin DH; Feldman RM; Sheu WP;
Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
[TBL] [Abstract][Full Text] [Related]
12. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides.
Martínez A; Sánchez M
Curr Med Res Opin; 2007 Mar; 23(3):595-9. PubMed ID: 17355740
[TBL] [Abstract][Full Text] [Related]
13. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide.
Tsukamoto H; Noma H; Mukai S; Ikeda H; Mishima HK
J Ocul Pharmacol Ther; 2005 Oct; 21(5):395-9. PubMed ID: 16245966
[TBL] [Abstract][Full Text] [Related]
17. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
19. [Azarga, a new and useful fixed combination in glaucoma treatment].
Călugăru M; Călugăru D
Oftalmologia; 2011; 55(3):38-46. PubMed ID: 22428291
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study.
Crichton AC; Harasymowycz P; Hutnik CM; Behki R; Boucher S; Ibrahim F; Rifkind AW; Solomon L; Liao C; Bastien NR; Sampalis JS
J Ocul Pharmacol Ther; 2010 Oct; 26(5):503-11. PubMed ID: 20874498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
